These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 28003008)

  • 1. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
    Cena H; Chiovato L; Nappi RE
    J Clin Endocrinol Metab; 2020 Aug; 105(8):e2695-709. PubMed ID: 32442310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
    Jensterle M; Pirš B; Goričar K; Dolžan V; Janež A
    Eur J Clin Pharmacol; 2015 Jul; 71(7):817-24. PubMed ID: 25991051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
    Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
    Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
    Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
    Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.
    Niafar M; Pourafkari L; Porhomayon J; Nader N
    Arch Gynecol Obstet; 2016 Mar; 293(3):509-15. PubMed ID: 26660657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF; Nilas L; Madsbad S; Holst JJ
    Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.
    Bader S; Bhatti R; Mussa B; Abusanana S
    Womens Health (Lond); 2024; 20():17455057241234530. PubMed ID: 38444070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.
    Lamos EM; Malek R; Davis SN
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):401-408. PubMed ID: 28276778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
    de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
    Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1167-79. PubMed ID: 27563838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome.
    Siamashvili M; Davis SN
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1081-1089. PubMed ID: 34015974
    [No Abstract]   [Full Text] [Related]  

  • 13. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
    Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
    Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
    Pugliese G; de Alteriis G; Muscogiuri G; Barrea L; Verde L; Zumbolo F; Colao A; Savastano S
    J Endocrinol Invest; 2023 Sep; 46(9):1761-1774. PubMed ID: 37093453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
    Han Y; Li Y; He B
    Reprod Biomed Online; 2019 Aug; 39(2):332-342. PubMed ID: 31229399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis.
    Ma R; Ding X; Wang Y; Deng Y; Sun A
    Medicine (Baltimore); 2021 Jun; 100(23):e26295. PubMed ID: 34115034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS.
    Xing C; Li C; He B
    J Clin Endocrinol Metab; 2020 Sep; 105(9):2950-63. PubMed ID: 32490533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.